---
layout: post
title: "Real-Time Oncology Review; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:59:56 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-15676
original_published: 2022-07-22 00:00:00 +0000
significance: 8.00
---

# Real-Time Oncology Review; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 22, 2022 00:00 UTC
**Document Number:** 2022-15676

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Real-Time Oncology Review (RTOR)." The purpose of this guidance is to provide recommendations to applicants on the process for submission of selected new drug applications (NDAs) and biologics license applications (BLAs) with oncology indications for review under RTOR.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/22/2022-15676/real-time-oncology-review-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-15676

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
